Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment
Phase 1
Completed
- Conditions
- Pancreatic Cancer
- Registration Number
- NCT00288925
- Lead Sponsor
- Zeria Pharmaceutical
- Brief Summary
To evaluate the safety of two doses of Z-360 with Gemcitabine administration for subjects with unresectable advanced pancreatic cancer in order to determine the optimal dosage for PhaseII study
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Subjects with unresectable locally advanced or metastatic pancreatic cancer
- KPS > 70%
- Life expectancy of at least 3 months
Exclusion Criteria
- received previous chemotherapy for the current indication
- received previous radiotherapy for the current indication
- Currently receiving chemotherapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Safety, Pharmacokinetics
- Secondary Outcome Measures
Name Time Method Tumour shrinkage, Tumour objective response rate
Trial Locations
- Locations (1)
Royal Free Hospital
🇬🇧London, United Kingdom